TOKYO--(BUSINESS WIRE)--Hakushindo Pharmaceutical Co., Ltd. (head office: Shinjuku-ku, Tokyo,
CEO Daizo Shimamura) provided research funding to the Project Research
Center For Clinical Trials and Preventative Medicine at the Hiroshima
University Graduate School of Biomedical & Health Sciences to carry out
the world's first clinical study regarding long-term (24 weeks) oral
intake of NMN (β-nicotinamide mononucleotide). The name of the trial is:
Evaluation of the effects of long-term ingestion of nicotinamide
mononucleotide (NMN). The purpose of the trial is to confirm an increase
in rejuvenating hormones, activation of mitochondria, and to confirm the
emergence of sirtuin genes 1 and 2.
Hakushindo Pharmaceutical has
recently transferred all of its shares to Shinkowa Pharmaceutical Co.,
Ltd. (head office: Chuo-ku, Tokyo, CEO, Megumi Tanaka).
The clinical trial on oral NMN intake is currently underway at the
Hiroshima University Graduate School of Biomedical & Health Sciences:
Project Research Center For Clinical Trials and Preventative Medicine.
UMIN
trial ID: UMIN000025739
http://rctportal.niph.go.jp/en/detail?trial_id=UMIN000025739
The NMN source used in the clinical trial at the Hiroshima University Graduate School of Biomedical & Health Sciences: Project Research Center For Clinical Trials and Preventative Medicine was purchased from Shinkowa Pharmaceutical Co., Ltd., and the completion of Hakushindo Pharmaceutical's defined role in this clinical trial is the reason for the transfer of the company's shares to Shinkowa Pharmaceutical Co., Ltd.
In the future, Hakushindo Pharmaceutical intends to actively carry out new clinical studies of NMN, as well as other related clinical studies.
Company profile
Company name: Hakushindo Pharmaceutical Co., Ltd.
Representative:
Daizo Shimamura
Location: Shinjuku-ku, Tokyo
Business
description: Health food and cosmetics sales business, clinical research
consignment